Literature DB >> 29150959

NONO ubiquitination is mediated by FBW7 and GSK3 β via a degron lost upon chromosomal rearrangement in cancer.

Luigi Alfano1, Antonella Caporaso2, Angela Altieri2, Caterina Costa1, Iris M Forte1, Carmelina A Iannuzzi1, Daniela Barone1, Luca Esposito1, Antonio Giordano1,2,3, Francesca Pentimalli1.   

Abstract

NONO is an RNA-binding protein involved in transcription, mRNA splicing, DNA repair, and checkpoint activation in response to UV radiation. NONO expression has been found altered in several tumor types, including prostate, colon, breast, melanoma, and in papillary renal carcinoma, in which an X chromosome inversion generates a NONO-TFE3 fusion protein. Upon such rearrangement, NONO loses its C-terminal domain. Through bioinformatics analysis, we identified a putative degron motif, known to be recognized by the Skp1-Cul1-F-box-protein (SCF) complex. Here, we evaluated how this domain could affect NONO protein biology. We showed that NONO interacts with the nuclear FBW7α isoform and its ubiquitination is regulated following modulation of the GSK3β kinase. Mutation of T428A/T432A within the degron impaired polyubiquitination upon FBW7α and GSK3β overexpression. Overall, our data suggest that NONO is likely subjected to proteasome-mediated degradation and add NONO to the list of proteins targeted by FBW7, which is itself often deregulated in cancer.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  E3 ubiquitin ligase; FBW7; NONO; TFE3; papillary renal carcinoma

Mesh:

Substances:

Year:  2017        PMID: 29150959     DOI: 10.1002/jcp.26269

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  3 in total

1.  NONO Is a Negative Regulator of SOX2 Promoter.

Authors:  Shanshan Liang; Hidehisa Takahashi; Tetsuro Hirose; Yasuhiro Kuramitsu; Shigetsugu Hatakeyama; Hironori Yoshiyama; Ruoyu Wang; Jun-Ichi Hamada; Hisashi Iizasa
Journal:  Cancer Genomics Proteomics       Date:  2020 Jul-Aug       Impact factor: 4.069

Review 2.  NONO and tumorigenesis: More than splicing.

Authors:  Peifu Feng; Ling Li; Tanggang Deng; Yan Liu; Neng Ling; Siyuan Qiu; Lin Zhang; Bo Peng; Wei Xiong; Lanqin Cao; Lei Zhang; Mao Ye
Journal:  J Cell Mol Med       Date:  2020-03-13       Impact factor: 5.310

3.  PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer.

Authors:  Xin-Ke Yin; Yun-Long Wang; Fei Wang; Wei-Xing Feng; Shao-Mei Bai; Wan-Wen Zhao; Li-Li Feng; Ming-Biao Wei; Cao-Litao Qin; Fang Wang; Zhi-Li Chen; Hong-Jun Yi; Yan Huang; Pei-Yi Xie; Taewan Kim; Ying-Nai Wang; Jun-Wei Hou; Chia-Wei Li; Quentin Liu; Xin-Juan Fan; Mien-Chie Hung; Xiang-Bo Wan
Journal:  Oncogene       Date:  2021-01-08       Impact factor: 9.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.